SILO
Silo Pharma, Inc.NASDAQHealthcare$0.35+2.95%ClosedMarket Cap: $2.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.75
P/S
39.53
EV/EBITDA
0.46
DCF Value
$0.42
FCF Yield
-163.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-602.8%
Operating Margin
-5937.0%
Net Margin
-5863.5%
ROE
-83.5%
ROA
-55.6%
ROIC
-61.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $18.0K | -1303.8% | $-786.5K | $-881.5K | $-0.07 | — |
| FY 2025 | $72.1K | -1128.9% | $-4.3M | $-4.2M | $-0.50 | — |
| Q3 2025 | $18.0K | -1291.2% | $-1.2M | $-1.1M | $-0.12 | — |
| Q2 2025 | $18.0K | 91.9% | $-1.2M | $-1.2M | $-0.19 | — |
| Q1 2025 | $18.0K | 91.9% | $-1.1M | $-1.0M | $-0.23 | — |
| Q4 2024 | $18.0K | -2118.3% | $-1.9M | $-1.7M | $-0.39 | — |
| FY 2024 | $72.1K | 91.9% | $-4.7M | $-4.4M | $-1.19 | — |
| Q3 2024 | $18.0K | 91.9% | $-1.0M | $-928.8K | $-0.22 | — |
| Q2 2024 | $18.0K | 91.9% | $-1.0M | $-931.8K | $-0.31 | — |
| Q1 2024 | $18.0K | 91.9% | $-879.5K | $-801.7K | $-0.28 | — |
| Q4 2023 | $18.0K | 91.9% | $-1.2M | $-1.1M | $-0.39 | — |
| FY 2023 | $72.1K | 91.9% | $-3.9M | $-3.7M | $-1.20 | — |